Coulter Partners places Gregory Reinaud as Chief Operating Officer of Proveca

Proveca is a specialist pharmaceutical company dedicated to providing licensed medicines for children. The Company develops and licenses medicines for children with long-term, chronic conditions, addressing the significant issue of children being prescribed adult medications that are not age appropriate. By collaborating with clinicians, parents, and caregivers, Proveca aims to improve the lives of children by providing safer and more effective treatment options.

Gregory Reinaud is a highly experienced healthcare leader with over 25 years in the pharmaceutical industry, known for his ability to drive growth and lead transformative change. He joins Proveca after a distinguished career that includes senior executive roles at McKinsey, GSK, and ViiV Healthcare. Greg’s expertise in bridging scientific innovation with commercial success is a key asset. During his tenure as General Manager at ViiV Healthcare Canada, he led the business and oversaw the launch of groundbreaking therapies, contributing to a significant sales increase. His track record of managing complex operations and leading high-performing teams makes him a perfect fit to help Proveca achieve its strategic goals.

Commenting on the appointment, Dr. Simon Bryson, CEO of Proveca said: “I am delighted to welcome Greg as COO, marking a pivotal moment in our journey as we continue our growth and global expansion, and position the company for long-term success.”

Simon Bryson also added: ”The chemistry with Coulter Partners was spot on from the start. They genuinely understood our core motivations for this critical role and brought a strong, rigorous methodology to the search, providing us with thorough and detailed candidate reports. The caliber of the candidate pool, including some excellent 'wild cards,' was truly impressive, and we are absolutely delighted with the final outcome.”

----

Gregory Reinaud, Chief Operating Officer, Proveca

Gregory Reinaud is a distinguished healthcare leader with over 25 years of experience in the pharmaceutical, consulting, and operations sectors. His career has spanned prestigious organizations, including McKinsey, GSK, and ViiV Healthcare, where he has progressed from strategy consulting to executive leadership. Greg is widely recognized for his consistent ability to turn around declining assets, launch transformative therapies, and drive significant growth for products, divisions, and entire companies. He holds a strong academic foundation with a BA/MA in Natural Sciences from Cambridge University and an MBA from INSEAD.

Throughout his career, Greg has demonstrated exceptional leadership in various senior roles, including General Manager, Chief Commercial Officer, and Executive Team Member. His experience across commercial, R&D, and corporate functions has enabled him to effectively bridge the gap between scientific innovation and commercial success. A notable achievement includes his tenure as GM at ViiV Healthcare Canada, where he led the business and oversaw the successful launch of groundbreaking HIV therapies, contributing to a significant sales increase. At GSK R&D, he optimized a multibillion-dollar R&D portfolio, leading to substantial improvement in ROI. His deep expertise in strategy development, portfolio management, and commercial operations makes him a valuable addition to the Proveca team.

About Proveca

About Coulter Partners